FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications

The FDA’s recently altered outlook on the evidence required for approval of rare disease drugs could have immediate benefits for companies including Skyhawk Therapeutics, Capricor Therapeutics and Biohaven.